Skip to main content

Trevi Therapeutics, Inc.

TRVI
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001563880

In the last 90 days, Trevi Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 218 institutions reported holding it in 13F filings for Q2 2026, worth $2.76B in total; Viking Global Investors is the only superinvestor holding it.

13F holders, Q2 2021

Institutional positions in Trevi Therapeutics, Inc. as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
17
−2 vs. Q1 2021
Shares held
12.5M
−650.2K (−5.0%) vs. Q1 2021
Total value
$28.1M
−$7.51M (−21.1%) vs. Q1 2021
New holders
2
5 more added
Sold out
4
3 more reduced

Compare with Q1 2021: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting TRVI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ2 2021: 17 institutions
Q1 2021: 19 institutionsQ2 2021: 17 institutionsQ3 2021: 18 institutionsQ4 2021: 17 institutionsQ1 2022: 23 institutionsQ2 2022: 32 institutionsQ3 2022: 40 institutionsQ4 2022: 37 institutionsQ1 2023: 36 institutionsQ2 2023: 53 institutionsQ3 2023: 55 institutionsQ4 2023: 63 institutionsQ1 2024: 80 institutionsQ2 2024: 77 institutionsQ3 2024: 93 institutionsQ4 2024: 110 institutionsQ1 2025: 137 institutionsQ2 2025: 154 institutionsQ3 2025: 164 institutionsQ4 2025: 184 institutionsQ1 2026: 198 institutionsQ2 2026: 218 institutions
Value heldQ2 2021: $28.1M
Q1 2021: $35.6MQ2 2021: $28.1MQ3 2021: $17.4MQ4 2021: $10.3MQ1 2022: $32.9MQ2 2022: $80.8MQ3 2022: $70.5MQ4 2022: $83.3MQ1 2023: $80.4MQ2 2023: $116.7MQ3 2023: $106.1MQ4 2023: $70.0MQ1 2024: $177.9MQ2 2024: $166.6MQ3 2024: $194.1MQ4 2024: $329.5MQ1 2025: $554.3MQ2 2025: $627.2MQ3 2025: $1.18BQ4 2025: $1.63BQ1 2026: $1.61BQ2 2026: $2.76B
Institutions holding TRVI and their total value by quarter
QuarterHoldersValue
Q2 2026218$2.76B
Q1 2026198$1.61B
Q4 2025184$1.63B
Q3 2025164$1.18B
Q2 2025154$627.2M
Q1 2025137$554.3M
Q4 2024110$329.5M
Q3 202493$194.1M
Q2 202477$166.6M
Q1 202480$177.9M
Q4 202363$70.0M
Q3 202355$106.1M
Q2 202353$116.7M
Q1 202336$80.4M
Q4 202237$83.3M
Q3 202240$70.5M
Q2 202232$80.8M
Q1 202223$32.9M
Q4 202117$10.3M
Q3 202118$17.4M
Q2 202117$28.1M
Q1 202119$35.6M

Institutions, Q2 2021

Shares, value and share of portfolio for each institution holding Trevi Therapeutics, Inc.; share changes are against Q1 2021.

Institutions holding TRVI in Q2 2021
InstitutionSharesValue% of portfolioChange in sharesAction
NEA Management Company, LLC5,940,796$13.4M0.17%00.0%Unchanged
TPG Group Holdings (SBS) Advisors, Inc.4,824,883$10.9M0.08%00.0%Unchanged
Omega Fund Management, LLC1,263,408$2.84M0.32%00.0%Unchanged
Vanguard Group Inc133,215$300.0K0.00%00.0%Unchanged
Renaissance Technologies LLC92,600$208.0K0.00%−29,249−24.0%Reduced
Geode Capital Management, LLC49,077$110.0K0.00%00.0%Unchanged
BlackRock Inc.44,180$99.0K0.00%+11,786+36.4%Added
WealthTrust Axiom LLC39,500$88.0K0.03%+1,000+2.6%Added
Bridgeway Capital Management, LLC34,600$78.0K0.00%−75,000−68.4%Reduced
Alberta Investment Management Corp25,000$56.0K0.00%+25,000New
Northern Trust Corp11,414$26.0K0.00%00.0%Unchanged
LPL Financial LLC10,000$23.0K0.00%00.0%Unchanged
Tower Research Capital LLC (TRC)4,187$10.0K0.00%+2,950+238.5%Added
First Manhattan Co3,500$7.00K0.00%+1,600+84.2%Added
UBS Group AG2,137$5.00K0.00%−241−10.1%Reduced
Wells Fargo & Company33$00.00%+9+37.5%Added
Barclays PLC100$00.00%+100New
FMR LLC0$00.00%−576,500−100.0%Sold out
Citadel Advisors LLC0$00.00%−10,617−100.0%Sold out
Morgan Stanley0$00.00%−1,000−100.0%Sold out
Bank of America Corp0$00.00%−16−100.0%Sold out